Mechanisms regulating T-cell infiltration and activity in solid tumors

Annals of Oncology

Volumn 28, Issue , 2017, Pages xii18-xii32

  Lanitis, E ^a   Dangaj, D ^a   Irving, M ^a   Coukos, George ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cancer; Immunotherapy; T cells; Tumor microenvironment

Indexed keywords

ANTHRACYCLINE; B7 ANTIGEN; CANCER TESTIS ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CHIMERIC ANTIGEN RECEPTOR; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; OXALIPLATIN; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; PROTEIN TYROSINE PHOSPHATASE SHP 1; T LYMPHOCYTE RECEPTOR; VASCULOTROPIN A;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CELL DENSITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA REPAIR; DOWN REGULATION; GLYCOLYSIS; HAPLOTYPE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHATIC SYSTEM; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALIGNANT NEOPLASM; MELANOMA; MERKEL CELL CARCINOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR EVOLUTION; NITROSYLATION; NON SMALL CELL LUNG CANCER; NUCLEAR REPROGRAMMING; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVIEW; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; VDJ RECOMBINATION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE;

HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES;

EID: 85039555967     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx238     Document Type: Review

References (299)

1. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986; 39: 585-589
2. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213
3. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964
4. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306
5. Hwang WT, Adams SF, Tahirovic E et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124: 192-198
6. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557
7. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12: 269-281
8. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348: 62-68
9. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
10. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454
11. Hamanishi J, Mandai M, Ikeda T et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015; 33: 4015-4022
12. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
13. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562
14. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813
15. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319
16. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520
17. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007; 13: 5271-5279
18. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
19. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571
20. Chen DS, Mellman I. Oncology meets immunology: the cancerimmunity cycle. Immunity 2013; 39: 1-10
21. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 2016; 27: 1492-1504
22. Dieu-Nosjean MC, Goc J, Giraldo NA et al. Tertiary lymphoid structures in cancer and beyond. Trends Immunol 2014; 35: 571-580
23. Goc J, Fridman WH, Hammond SA et al. Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. Oncoimmunology 2014; 3: e28976
24. Zhu W, Germain C, Liu Z et al. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality. Oncoimmunology 2015; 4: e1051922
25. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003; 21: 139-176
26. Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-3085
27. Salerno EP, Olson WC, McSkimming C et al. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer 2014; 134: 563-574
28. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14: 1014-1022
29. Fuertes MB, Kacha AK, Kline J et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8(alpha)+ dendritic cells. J Exp Med 2011; 208: 2005-2016
30. Broz ML, Binnewies M, Boldajipour B et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014; 26: 638-652
31. Woo SR, Fuertes MB, Corrales L et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41: 830-842
32. Corrales L, Glickman LH, McWhirter SM et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep 2015; 11: 1018-1030
33. Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cellinflamed tumor microenvironment. Trends Immunol 2015; 36: 250-256
34. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumorinfiltrating dendritic cells in cancer pathogenesis. J Immunol 2015; 194: 2985-2991
35. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135-146
36. Irving M, Zoete V, Hebeisen M et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012; 287: 23068-23078
37. Vonderheide RH, June CH. Engineering T cells for cancer: our synthetic future. Immunol Rev 2014; 257: 7-13
38. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl JMed 2014; 371: 2189-2199
39. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in nonsmall cell lung cancer. Science 2015; 348: 124-128
40. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-581
41. van Rooij N, van Buuren MM, Philips D et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31: e439-e442
42. Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344: 641-645
43. Anagnostou V, Smith KN, Forde PM et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7: 264-276
44. Spranger S, Luke JJ, Bao R et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA 2016; 113: E7759-E7768
45. Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med 2016; 374: 2542-2552
46. Lipson EJ, Vincent JG, Loyo M et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1: 54-63
47. Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn 2001; 3: 98-104
48. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002; 109 Suppl: S45-S55
49. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 3-13
50. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273
51. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127: 249-256
52. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570
53. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015; 523: 231-235
54. Peng W, Chen JQ, Liu C et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016; 6: 202-216
55. Hall A, Meyle KD, Lange MK et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 2013; 4: 584-599
56. Pivarcsi A, Muller A, Hippe A et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci USA 2007; 104: 19055-19060
57. Strickland KC, Howitt BE, Shukla SA et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016; 7: 13587-13598
58. van Gool IC, Eggink FA, Freeman-Mills L et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015; 21: 3347-3355
59. Prall F, Duhrkop T, Weirich V et al. Prognostic role of CD8+ tumorinfiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35: 808-816
60. Iida N, Dzutsev A, Stewart CA et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970
61. Viaud S, Saccheri F, Mignot G et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976
62. Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084-1089
63. Vetizou M, Pitt JM, Daillere R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079-1084
64. Krummel MF, Bartumeus F, Gerard A. T cell migration, search strategies and mechanisms. Nat Rev Immunol 2016; 16: 193-201
65. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014; 32: 659-702
66. Woolf E, Grigorova I, Sagiv A et al. Lymph node chemokines promote sustained T lymphocyte motility without triggering stable integrin adhesiveness in the absence of shear forces. Nat Immunol 2007; 8: 1076-1085
67. Katakai T, Habiro K, Kinashi T. Dendritic cells regulate high-speed interstitial T cell migration in the lymph node via LFA-1/ICAM-1. J Immunol 2013; 191: 1188-1199
68. Bajenoff M, Egen JG, Koo LY et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006; 25: 989-1001
69. Mueller SN, Hosiawa-Meagher KA, Konieczny BT et al. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 2007; 317: 670-674
70. Ferguson AR, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J Immunol 2010; 184: 4079-4086
71. Sallusto F, Kremmer E, Palermo B et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999; 29: 2037-2045
72. Groom JR, Richmond J, Murooka TT et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity 2012; 37: 1091-1103
73. Hugues S, Scholer A, Boissonnas A et al. Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses. Nat Immunol 2007; 8: 921-930
74. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011; 317: 664-673
75. Gonzalez-Martin A, Gomez L, Lustgarten J et al. Maximal T cellmediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011; 71: 5455-5466
76. Sung JH, Zhang H, Moseman EA et al. Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes. Cell 2012; 150: 1249-1263
77. Kastenmuller W, Brandes M, Wang Z et al. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. Immunity 2013; 38: 502-513
78. Kurachi M, Kurachi J, Suenaga F et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med 2011; 208: 1605-1620
79. Hong M, Puaux AL, Huang C et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71: 6997-7009
80. Hu JK, Kagari T, Clingan JM, Matloubian M. Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. Proc Natl Acad Sci USA 2011; 108: E118-E127
81. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008; 68: 8437-8445
82. Hensbergen PJ, Wijnands PG, SchreursMWet al. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother 2005; 28: 343-351
83. Peng W, Liu C, Xu C et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72: 5209-5218
84. Ulloa-Montoya F, Louahed J, Dizier B et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31: 2388-2395
85. Mikucki ME, Fisher DT, Matsuzaki J et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015; 6: 7458
86. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012; 167: 195-205
87. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612
88. Schlecker E, Stojanovic A, Eisen C et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189: 5602-5611
89. Liu J, Zhang N, Li Q et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 2011; 6: e19495
90. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51
91. Choi HS, Ha SY, Kim HM et al. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget 2016; 7: 7940-7951
92. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015; 5: 15179
93. Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol 2014; 4: 137
94. Facciabene A, Peng X, Hagemann IS et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-230
95. Righi E, Kashiwagi S, Yuan J et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011; 71: 5522-5534
96. Wang Z, Ma Q, Liu Q et al. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer 2008; 99: 1695-1703
97. Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015; 527: 249-253
98. Molon B, Ugel S, Del Pozzo F et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208: 1949-1962
99. Proost P, Mortier A, Loos T et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007; 110: 37-44
100. Hogg N, Patzak I, Willenbrock F. The insider's guide to leukocyte integrin signalling and function. Nat Rev Immunol 2011; 11: 416-426
101. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-836
102. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66
103. Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol 2015; 33: 55-63
104. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat 2007; 10: 109-120
105. Griffioen AW, Damen CA, Martinotti S et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111-1117
106. Demunter A, De Wolf-Peeters C, Degreef H et al. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001; 438: 485-491
107. Egidy G, Eberl LP, Valdenaire O et al. The endothelin system in human glioblastoma. Lab Invest 2000; 80: 1681-1689
108. Tanaka T, Sho M, Takayama T et al. Endothelin B receptor expression correlates with tumour angiogenesis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2014; 110: 1027-1033
109. Buckanovich RJ, Facciabene A, Kim S et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14: 28-36
110. Motz GT, Santoro SP, Wang LP et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607-615
111. Yu JS, Lee PK, Ehtesham M et al. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 2003; 64: 55-61
112. Zang X, Sullivan PS, Soslow RA et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010; 23: 1104-1112
113. Kraan J, van den Broek P, Verhoef C et al. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br J Cancer 2014; 111: 149-156
114. Qin X, Zhang H, Ye D et al. B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma. Onco Targets Ther 2013; 6: 1667-1673
115. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 2002; 169: 3581-3588
116. Rodig N, Ryan T, Allen JA et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003; 33: 3117-3126
117. Wu FH, Yuan Y, Li D et al. Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway. Oncol Rep 2010; 24: 693-699
118. Huang X, Bai X, Cao Y et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010; 207: 505-520
119. Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 2006; 103: 10391-10396
120. Mulligan JK, YoungMR. Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol Immunother 2010; 59: 267-277
121. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77-87
122. Casos K, Siguero L, Fernandez-Figueras MT et al. Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation. Microvasc Res 2011; 81: 261-268
123. Taflin C, Favier B, Baudhuin J et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA 2011; 108: 2891-2896
124. Lider O, Mekori YA, Miller T et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20: 493-499
125. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401
126. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348: 74-80
127. Kano A. Tumor cell secretion of soluble factor(s) for specific immunosuppression. Sci Rep 2015; 5: 8913
128. Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 2013; 35: 123-137
129. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188: 21-28
130. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125: 3356-3364
131. Mandai M, Hamanishi J, Abiko K et al. Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of proand antitumor immunity. Clin Cancer Res 2016; 22: 2329-2334
132. Spranger S, Spaapen RM, Zha Y et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5: 200ra116
133. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265
134. Pandiyan P, Zheng L, Ishihara S et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353-1362
135. Liang B, Workman C, Lee J et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180: 5916-5926
136. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227-242
137. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-1183
138. Johnston RJ, Comps-Agrar L, Hackney J et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-937
139. Sledzinska A, Menger L, Bergerhoff K et al. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol 2015; 9: 1936-1965
140. Dolton GM, Sathish JG, Matthews RJ. Protein tyrosine phosphatases as negative regulators of the immune response. Biochm Soc Trans 2006; 34: 1041-1045
141. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 2009; 228: 342-359
142. Lutz-Nicoladoni C, Wolf D, Sopper S. Modulation of immune cell functions by the E3 ligase Cbl-b. Front Oncol 2015; 5: 58
143. Riese MJ, Moon EK, Johnson BD, Albelda SM. Diacylglycerol kinases (DGKs): novel targets for improving T cell activity in cancer. Front Cell Dev Biol 2016; 4: 108
144. O'Brien S, Thomas RM, Wertheim GB et al. Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production. J Immunol 2014; 192: 5118-5129
145. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15: 486-499
146. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033
147. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-270
148. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol 2013; 31: 259-283
149. Wang R, Green DR. Metabolic reprogramming and metabolic dependency in T cells. Immunol Rev 2012; 249: 14-26
150. Chang CH, Qiu J, O'Sullivan D et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015; 162: 1229-1241
151. Zhao E, Maj T, Kryczek I et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 2016; 17: 95-103
152. Fischer K, Hoffmann P, Voelkl S et al. Inhibitory effect of tumor cellderived lactic acid on human T cells. Blood 2007; 109: 3812-3819
153. Kouidhi S, Noman MZ, Kieda C et al. Intrinsic and tumor microenvironment-induced metabolism adaptations of T cells and impact on their differentiation and function. Front Immunol 2016; 7: 114
154. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5: 641-654
155. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109: 1568-1573
156. Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41: 614-634
157. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64: 5839-5849
158. Friberg M, Jennings R, Alsarraj M et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101: 151-155
159. Frumento G, Rotondo R, Tonetti M et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-468
160. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-221
161. Baban B, Chandler PR, Sharma MD et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183: 2475-2483
162. Patsoukis N, Bardhan K, Chatterjee P et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 2015; 6: 6692
163. Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-9553
164. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450-461
165. Dudley ME, Wunderlich JR, Shelton TE et al. Generation of tumorinfiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332-342
166. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102: 127-141
167. Butler MO, Lee JS, Ansen S et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigenpresenting cell. Clin Cancer Res 2007; 13: 1857-1867
168. Butler MO, Friedlander P, Milstein MI et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 2011; 3: 80ra34
169. Rapoport AP, Stadtmauer EA, Binder-Scholl GK et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015; 21: 914-921
170. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014; 257: 56-71
171. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3: 388-398
172. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev 2016; 30: 157-167
173. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-2635
174. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517
175. Lamers CH, Sleijfer S, Vulto AG et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20-e22
176. Lamers CH, Sleijfer S, van Steenbergen S et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Mol Ther 2013; 21: 904-912
177. Morgan RA, Yang JC, Kitano M et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851
178. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 2014; 5: 235
179. Lanitis E, Poussin M, Klattenhoff AW et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013; 1: 43-53
180. Wu CY, Roybal KT, Puchner EM et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015; 350: aab4077
181. Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology 2014; 3: e970027
182. Moon EK, Wang LC, Dolfi DV et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptortransduced human T cells in solid tumors. Clin Cancer Res 2014; 20: 4262-4273
183. Cherkassky L, Morello A, Villena-Vargas J et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 2016; 126: 3130-3144
184. John LB, Devaud C, Duong CP et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013; 19: 5636-5646
185. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016; 13: 273-290
186. Di Stasi A, De Angelis B, Rooney CM et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392-6402
187. Moon EK, Carpenito C, Sun J et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011; 17: 4719-4730
188. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014; 257: 83-90
189. Curran KJ, Seinstra BA, Nikhamin Y et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 2015; 23: 769-778
190. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264
191. Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015; 7: 365-377
192. Califano R, Kerr K, Morgan RD et al. Immune checkpoint blockade: a new era for non-small cell lung cancer. Curr Oncol Rep 2016; 18: 59
193. Mahoney KM, Freeman GJ, McDermott DF. The next immunecheckpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015; 37: 764-782
194. Im SJ, HashimotoM, GernerMY et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016; 537: 417-421
195. Utzschneider DT, Charmoy M, Chennupati V et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 2016; 45: 415-427
196. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492-499
197. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-824
198. Grosso JF, Goldberg MV, Getnet D et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182: 6659-6669
199. Sakuishi K, Apetoh L, Sullivan JM et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194
200. Le Mercier I, Chen W, Lines JL et al. VISTA regulates the development of protective antitumor immunity. Cancer Res 2014; 74: 1933-1944
201. Yonezawa A, Dutt S, Chester C et al. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin Cancer Res 2015; 21: 3113-3120
202. Linch SN, McNamara MJ, Redmond WL. OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol 2015; 5: 34
203. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25: 230-237
204. Weigelin B, Bolanos E, Rodriguez-Ruiz ME et al. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage? Cancer Immunol Immunother 2016; 65: 493-497
205. Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front Oncol 2015; 5: 117
206. Roberts DJ, Franklin NA, Kingeter LM et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010; 33: 769-779
207. Cohen AD, Diab A, Perales MA et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006; 66: 4904-4912
208. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 360-367
209. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-135
210. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013; 19: 1035-1043
211. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009; 21: 265-272
212. Mangsbo SM, Broos S, Fletcher E et al. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res 2015; 21: 1115-1126
213. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-1616
214. Weiss JM, Wiltout RH. Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents. Oncoimmunology 2014; 3: e954483
215. Beatty GL, Torigian DA, Chiorean EG et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013; 19: 6286-6295
216. Zhu Y, Knolhoff BL, Meyer MA et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74: 5057-5069
217. Holmgaard RB, Zamarin D, Lesokhin A et al. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 2016; 6: 50-58
218. Xu J, Escamilla J, Mok S et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013; 73: 2782-2794
219. Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 2012; 109: 7841-7846
220. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013; 62: 1137-1148
221. Platten M, von Knebel Doeberitz N, Oezen I et al. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol 2014; 5: 673
222. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003; 102: 1449-1457
223. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277
224. Kandalaft LE, Chiang CL, Tanyi J et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med 2013; 11: 149
225. Chiang CL, Kandalaft LE, Tanyi J et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013; 19: 4801-4815
226. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15: 6267-6276
227. Tureci O, Vormehr M, Diken M et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res 2016; 22: 1885-1896
228. Carreno BM, Magrini V, Becker-Hapak M et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348: 803-808
229. Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534: 396-401
230. Galluzzi L, Buque A, Kepp O et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28: 690-714
231. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73
232. Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61
233. Palombo F, Focaccetti C, Barnaba V. Therapeutic implications of immunogenic cell death in human cancer. Front Immunol 2014; 4: 503
234. Sistigu A, Yamazaki T, Vacchelli E et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301-1309
235. Pfirschke C, Engblom C, Rickelt S et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016; 44: 343-354
236. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14: 642-662
237. Aurelian L. Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther 2016; 9: 2627-2637
238. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14: 559-567
239. Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma. Immunotherapy 2015; 7: 611-619
240. Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res 2015; 21: 5543-5551
241. Zamarin D, Holmgaard RB, Subudhi SK et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6: 226ra232
242. Puzanov I, Milhem MM, Minor D et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 2016; 34: 2619-2626
243. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62
244. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
245. Winkler F, Kozin SV, Tong RT et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-563
246. Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-3736
247. Dirkx AE, oude EgbrinkMG, Castermans K et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20: 621-630
248. Li B, Lalani AS, Harding TC et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12: 6808-6816
249. Manning EA, Ullman JG, Leatherman JM et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13: 3951-3959
250. Shrimali RK, Yu Z, Theoret MR et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-6180
251. Kandalaft LE, Motz GT, Busch J, Coukos G. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol 2011; 344: 129-148
252. Miller DW, Vosseler S, Mirancea N et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol 2005; 167: 1389-1403
253. Sacchi A, Gasparri A, Gallo-Stampino C et al. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculaturetargeted tumor necrosis factor-alpha. Clin Cancer Res 2006; 12: 175-182
254. Curnis F, Sacchi A, Borgna L et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18: 1185-1190
255. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110: 475-482
256. Calcinotto A, Grioni M, Jachetti E et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012; 188: 2687-2694
257. Palazon A, Teijeira A, Martinez-Forero I et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011; 71: 801-811
258. Wong PP, Bodrug N, Hodivala-Dilke KM. Exploring novel methods for modulating tumor blood vessels in cancer treatment. Curr Biol 2016; 26: R1161-R1166
259. Wong PP, Demircioglu F, Ghazaly E et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 2015; 27: 123-137
260. Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015; 5: 202
261. Hodi FS, Lawrence D, Lezcano C et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2: 632-642
262. Wu X, Giobbie-Hurder A, Liao X et al. VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol Res 2016; 4: 858-868
263. Wallin JJ, Bendell JC, Funke R et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016; 7: 12624
264. Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet 2016; 17: 630-641
265. Bhadury J, Nilsson LM, Muralidharan SV et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014; 111: E2721-E2730
266. Yang X, Han H, De Carvalho DD et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014; 26: 577-590
267. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185
268. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112
269. Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478
270. Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483
271. Weber J, Salgaller M, Samid D et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994; 54: 1766-1771
272. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496-5503
273. Odunsi K, Matsuzaki J, James SR et al. Epigenetic potentiation of NYESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014; 2: 37-49
274. Chiappinelli KB, Strissel PL, Desrichard A et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2016; 164: 1073
275. Roulois D, Loo Yau H, Singhania R et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015; 162: 961-973
276. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin 2017; 67: 65-85
277. Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol 2012; 2: 191
278. Reynders K, De Ruysscher D. Radiotherapy and immunotherapy: improving cancer treatment through synergy. Prog Tumor Res 2015; 42: 67-78
279. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-1271
280. Matsumura S, Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 2010; 173: 418-425
281. Lugade AA, Sorensen EW, Gerber SA et al. Radiation-induced IFNgamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180: 3132-3139
282. Chakraborty M, Abrams SI, Coleman CN et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004; 64: 4328-4337
283. Wei S, Egenti MU, Teitz-Tennenbaum S et al. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother 2013; 36: 124-132
284. Quarmby S, Hunter RD, Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res 2000; 20: 3375-3381
285. Lugade AA, Moran JP, Gerber SA et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174: 7516-7523
286. Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996; 56: 5150-5155
287. Klug F, Prakash H, Huber PE et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24: 589-602
288. De Palma M, Coukos G, Hanahan D. A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. Cancer Cell 2013; 24: 559-561
289. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11: 728-734
290. Dewan MZ, Galloway AE, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-5388
291. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124: 687-695
292. Twyman-Saint Victor C, Rech AJ, Maity A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520: 373-377
293. PD-L1 upregulation drives escape from anti-CTLA4 and radiation therapy. Cancer Discov 2015; 5: OF13
294. Leavy O. Immunotherapy: a triple blow for cancer. Nat Rev Cancer 2015; 15: 258-259
295. Yokouchi H, Yamazaki K, Chamoto K et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci 2008; 99: 361-367
296. Chakraborty M, Abrams SI, Camphausen K et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170: 6338-6347
297. Witek M, Blomain ES, Magee MS et al. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys 2014; 88: 1188-1195
298. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931
299. Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer 2016; 2: 286-294